BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol 2019;71:1329-38. [PMID: 30835950 DOI: 10.1002/art.40876] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Kermani TA, Warrington KJ, Dua AB. Treatment Guidelines in Vasculitis. Rheumatic Disease Clinics of North America 2022. [DOI: 10.1016/j.rdc.2022.03.006] [Reference Citation Analysis]
2 Schmitt C, Brockwell L, Giraudon M, Zucchetto M, Christ L, Bannert B, Daikeler T, Villiger PM. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. Arthritis Res Ther 2022;24:133. [PMID: 35659282 DOI: 10.1186/s13075-022-02815-9] [Reference Citation Analysis]
3 Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev 2022;5:CD013484. [PMID: 35560150 DOI: 10.1002/14651858.CD013484.pub3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Bouffard MA, Prasad S, Unizony S, Costello F. Does Tocilizumab Influence Ophthalmic Outcomes in Giant Cell Arteritis? J Neuroophthalmol 2022. [PMID: 35482901 DOI: 10.1097/WNO.0000000000001514] [Reference Citation Analysis]
5 Conticini E, Hellmich B, Frediani B, Csernok E, Löffler C. Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis. Scand J Rheumatol 2022;:1-7. [PMID: 35383517 DOI: 10.1080/03009742.2022.2047311] [Reference Citation Analysis]
6 Cid MC, Unizony SH, Blockmans D, Brouwer E, Dagna L, Dasgupta B, Hellmich B, Molloy E, Salvarani C, Trapnell BC, Warrington KJ, Wicks I, Samant M, Zhou T, Pupim L, Paolini JF; KPL-301-C001 Investigators. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022:annrheumdis-2021-221865. [PMID: 35264321 DOI: 10.1136/annrheumdis-2021-221865] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
7 Sandovici M, van der Geest N, van Sleen Y, Brouwer E. Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open 2022;8:e001652. [PMID: 35149602 DOI: 10.1136/rmdopen-2021-001652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kuret T, Frank-bertoncelj M, Lakota K, Žigon P, Thallinger GG, Kopitar AN, Čučnik S, Tomšič M, Hočevar A, Sodin-šemrl S. From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide. Front Med 2022;8:827095. [DOI: 10.3389/fmed.2021.827095] [Reference Citation Analysis]
9 Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, Espígol-Frigolé G, Ríos-Garcés R, Marco-Hernández J, Denuc A, Kamberovic F, Pérez-Galán P, Joseph A, D'Andrea A, Bondensgaard K, Cid MC, Paolini JF. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 2022:annrheumdis-2021-220873. [PMID: 35045965 DOI: 10.1136/annrheumdis-2021-220873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
10 Hellmich B, Henes JC. [Biologics for connective tissue diseases and vasculitides]. Internist (Berl) 2022. [PMID: 35029701 DOI: 10.1007/s00108-021-01249-w] [Reference Citation Analysis]
11 Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, Grayson PC, McAdoo SP, Mason JC, Owen C, Weyand CM, Youngstein T, Dhaun N. Large-vessel vasculitis. Nat Rev Dis Primers 2022;7:93. [PMID: 34992251 DOI: 10.1038/s41572-021-00327-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Sugihara T, Nakaoka Y, Uchida HA, Yoshifuji H, Maejima Y, Watanabe Y, Amiya E, Tanemoto K, Miyata T, Umezawa N, Manabe Y, Ishizaki J, Shirai T, Nagafuchi H, Hasegawa H, Miyamae T, Niiro H, Ito S, Ishii T, Isobe M, Harigai M. Establishing Clinical Remission Criteria and the Framework of a Treat-To-Target Algorithm for Takayasu arteritis: Results of a Delphi Exercise Carried out by an Expert Panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for intractable vasculitis. Mod Rheumatol 2021:roab081. [PMID: 34850081 DOI: 10.1093/mr/roab081] [Reference Citation Analysis]
13 Esen I, Jiemy WF, van Sleen Y, van der Geest KSM, Sandovici M, Heeringa P, Boots AMH, Brouwer E. Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. J Clin Med 2021;10:4958. [PMID: 34768479 DOI: 10.3390/jcm10214958] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
14 Sebastian A, Coath F, Innes S, Jackson J, van der Geest KSM, Dasgupta B. Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis. Rheumatol Adv Pract 2021;5:rkab059. [PMID: 34514295 DOI: 10.1093/rap/rkab059] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Felten L, Leuchten N, Aringer M. Glucocorticoid dosing and relapses in giant cell arteritis-a single center cohort study. Rheumatology (Oxford) 2021:keab677. [PMID: 34487149 DOI: 10.1093/rheumatology/keab677] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev 2021;8:CD013484. [PMID: 34420204 DOI: 10.1002/14651858.CD013484.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Hoepfner M, Witte T. [Polymyalgia rheumatica and giant cell arteritis]. MMW Fortschr Med 2021;163:48-56. [PMID: 34370253 DOI: 10.1007/s15006-021-0086-2] [Reference Citation Analysis]
18 Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the Treatment of Giant Cell Arteritis. Arthritis Care Res (Hoboken) 2021;73:893-7. [PMID: 32248659 DOI: 10.1002/acr.24200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
19 Kaushik M, Ponte C, Mollan SP. Current advances in giant cell arteritis. Curr Opin Neurol 2021;34:133-41. [PMID: 33230039 DOI: 10.1097/WCO.0000000000000889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Ponte C, Monti S, Scirè CA, Delvino P, Khmelinskii N, Milanesi A, Teixeira V, Brandolino F, Saraiva F, Montecucco C, Fonseca JE, Schmidt WA, Luqmani RA. Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. Ann Rheum Dis 2021:annrheumdis-2021-220306. [PMID: 34215646 DOI: 10.1136/annrheumdis-2021-220306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Garvey TD, Koster MJ, Warrington KJ. My Treatment Approach to Giant Cell Arteritis. Mayo Clin Proc 2021;96:1530-45. [PMID: 34088416 DOI: 10.1016/j.mayocp.2021.02.013] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Matza MA, Fernandes AD, Stone JH, Unizony SH. Reply. Arthritis Care Res 2021;73:1059-60. [DOI: 10.1002/acr.24378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis 2021:annrheumdis-2021-220347. [PMID: 34049857 DOI: 10.1136/annrheumdis-2021-220347] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
24 Sadun A, Gordon L. Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis? J Neuroophthalmol 2020;40:117-21. [PMID: 31834197 DOI: 10.1097/WNO.0000000000000869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony SH, Bao M. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. The Lancet Rheumatology 2021;3:e328-36. [DOI: 10.1016/s2665-9913(21)00038-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
26 Hellmich B. [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?]. Z Rheumatol 2021;80:322-31. [PMID: 33710440 DOI: 10.1007/s00393-021-00975-8] [Reference Citation Analysis]
27 Arias M, Heydari-Kamjani M, Kesselman MM. Giant Cell Arteritis and Cardiac Comorbidity. Cureus 2021;13:e13391. [PMID: 33754114 DOI: 10.7759/cureus.13391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Nölle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zänker M, Hellmich B. [S2k guidelines: management of large-vessel vasculitis]. Z Rheumatol 2020;79:67-95. [PMID: 33156399 DOI: 10.1007/s00393-020-00893-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
29 Calderón-Goercke M, Castañeda S, Aldasoro V, Villa I, Moriano C, Romero-Yuste S, Narváez J, Gómez-Arango C, Pérez-Pampín E, Melero R, Becerra-Fernández E, Revenga M, Álvarez-Rivas N, Galisteo C, Sivera F, De Miguel E, Prieto-Peña D, González-Gay MÁ, Hernández JL, Blanco R; Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. Semin Arthritis Rheum 2021;51:387-94. [PMID: 33607384 DOI: 10.1016/j.semarthrit.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lee H, Tedeschi SK, Chen SK, Monach PA, Kim E, Liu J, Pethoe-Schramm A, Yau V, Kim SC. Identification of Acute Giant Cell Arteritis in Real-World Data Using Administrative Claims-Based Algorithms. ACR Open Rheumatol 2021;3:72-8. [PMID: 33491920 DOI: 10.1002/acr2.11218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Serling-Boyd N, Stone JH. Recent advances in the diagnosis and management of giant cell arteritis. Curr Opin Rheumatol 2020;32:201-7. [PMID: 32168069 DOI: 10.1097/BOR.0000000000000700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
32 Simon S, Ninan J, Hissaria P. Diagnosis and management of giant cell arteritis: Major review. Clin Exp Ophthalmol 2021;49:169-85. [PMID: 33426764 DOI: 10.1111/ceo.13897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Hellmich B, Águeda AF, Monti S, Luqmani R. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. Curr Rheumatol Rep 2020;22:84. [PMID: 33044642 DOI: 10.1007/s11926-020-00964-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
34 Matza MA, Fernandes AD, Stone JH, Unizony SH. Reply. Arthritis Care Res (Hoboken) 2021;73:1057-8. [PMID: 32961035 DOI: 10.1002/acr.24454] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Pfeil A, Franz M, Wolf G, Freesmeyer M. Refractory giant cell arteritis: the value of clinical symptoms and imaging. BMJ Case Rep 2020;13:e237623. [PMID: 32878842 DOI: 10.1136/bcr-2020-237623] [Reference Citation Analysis]
36 Schmidt WA, Dasgupta B, Luqmani R, Unizony SH, Blockmans D, Lai Z, Kurrasch RH, Lazic I, Brown K, Rao R. A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. Rheumatol Ther 2020;7:793-810. [PMID: 32844378 DOI: 10.1007/s40744-020-00227-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
37 Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol 2020;16:481-95. [DOI: 10.1038/s41584-020-0458-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
38 Robblee J, Singh RH. Headache in the Older Population: Causes, Diagnoses, and Treatments. Curr Pain Headache Rep 2020;24. [DOI: 10.1007/s11916-020-00866-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Res Ther 2020;22:72. [PMID: 32264967 DOI: 10.1186/s13075-020-02171-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
40 Nielsen BD, Gormsen LC. 18F-Fluorodeoxyglucose PET/Computed Tomography in the Diagnosis and Monitoring of Giant Cell Arteritis. PET Clin 2020;15:135-45. [PMID: 32145884 DOI: 10.1016/j.cpet.2019.11.007] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Michaud M, Catros F, Gaches F. Usefulness of serum amyloid a protein dosage for monitoring patients receiving tocilizumab. Eur J Intern Med 2020;74:115-6. [PMID: 31926783 DOI: 10.1016/j.ejim.2019.12.011] [Reference Citation Analysis]
42 de Boysson H, Liozon E, Espitia O, Daumas A, Vautier M, Lambert M, Parienti J, Granel B, Dumont A, Sultan A, Manrique A, Saadoun D, Ly KH, Agard C, Aouba A. Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. Journal of Autoimmunity 2019;103:102283. [DOI: 10.1016/j.jaut.2019.05.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
43 van Sleen Y, Graver JC, Abdulahad WH, van der Geest KSM, Boots AMH, Sandovici M, Brouwer E. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. Front Immunol 2019;10:1981. [PMID: 31507597 DOI: 10.3389/fimmu.2019.01981] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]